Graph AI has raised $13.3 million in Series A financing led by Insight Partners to address the operational inefficiencies and regulatory complexity facing modern pharmacovigilance and patient safety teams.
Insight Partners led the investment round, with participation from existing investor Bessemer Venture Partners.
Graph AI develops Graph Safety, an AI-native pharmacovigilance platform designed to automate patient safety workflows while preserving traceability, accountability, and human oversight.
Since raising its Seed round in October 2025, Graph AI has brought two modules to market: /intake, which captures and triages incoming adverse-event reports across every channel, and /nucleus, an intelligent safety database that automates case processing end-to-end.
A third module, /report, for automated aggregate reporting, is also launching this September. In live deployments, Graph Safety has reduced case processing turnaround time from more than three hours to under 10 minutes – a reduction of more than 90% and lowered operating costs by up to 66%.
Graph AI, founded in 2024, has already onboarded pharmaceutical and biotech customers across North America and other markets, and secured design partnerships for the modules ahead, including /signal, which surfaces emerging safety signals and patterns across cases.
Commenting on the fundraise, Raghav Parvataraju, CEO of Graph AI, said: “Pharmacovigilance has traditionally scaled against rising case volumes by adding people and processes around legacy systems. We believe intelligence can change that. Graph Safety gives safety experts an intelligent system that takes on operational complexity, while keeping traceability, accountability, and human oversight at the center. We are not replacing human judgment—we are building technology that allows experts to apply it where it matters most.”
VC Funding Trends
Digital health startups, including regulatory and clinical compliance solutions providers, have raised $20+ billion in funding so far this year.
More recently, Cheiron, the operating system for drug programs, raised $8 million in a Seed round to build its proprietary Life Sciences Knowledge Graph (LKG) — a structured intelligence layer connecting the world’s biomedical, clinical, regulatory, patent, and commercial knowledge into a single model.
In another deal, just 17 months after emerging from stealth, two-time entrepreneur and former Y Combinator partner Surbhi Sarna has raised $95 million for Collate, which developed AI tools to automate life sciences paperwork, at a valuation approaching $1 billion, according to Forbes.